Alembic Pharmaceuticals Ltd Share Price
As on 17 April 2025 at 21:24 IST
About Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd stands as a prominent figure in the pharmaceutical industry. It boasts a rich history dating back to its founding in the year 1907. With over a century of experience, this Gujarat-based company has established itself as a key player in the healthcare sector. It specializes in the manufacture and marketing of branded and generic drugs, as well as active pharmaceutical ingredients (APIs). Headquartered in the city of Vadodara, Alembic’s product portfolio is diverse. The company’s products encompasses antibiotics, anti-infectives, analgesics, and anti-inflammatory drugs, showcasing its expertise in this area. +
The Current prices are delayed, log in for live prices
LOGINOver 1 Month
3.64%
Over 6 Months
-28.43%
Over 1 Year
-11.77%
Over 3 Years
9.91%
Alembic Pharmaceuticals Ltd Summary
Close
₹849.90
Open
₹846.60
High
₹860.95
Low
₹842.75
Volume
3,00,164
Net Turnover (in Cr)
₹25.53
52Wk High
₹1,303.90
52Wk Low
₹725.20
52Wk High / Low
725.20
1,303.90
Alembic Pharmaceuticals Ltd Fundamentals
Key Financial Data
Market Cap (in Cr)
₹16,705.90
EPS (TTM)
31.49
Book Value (BV)
255.98
Div. Yield
1.29
%
P/E (TTM)
26.54
Price/Book Value
3.32
Delivery %
38.93
%
Face Value
2
Key Ratios
PE Ratio
28.97
PB Ratio
3.93
EV to Sales
3.37
PEG Ratio
0.31
ROA
12.09
ROE
14.30
Debt-Equity
0.13
Net Profit Margin
11.35
Operating Profit Margin
17.53
Alembic Pharmaceuticals Ltd Financials
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Total Revenue | 6,256.93 | 5,655.36 | 5,356.25 | 5,480.42 | 4,610.69 |
| Total Expenses | 5,624.13 | 5,269.86 | 4,736.14 | 4,112.34 | 3,567.22 |
| Profit Before Tax | 631.83 | 354.59 | 625.39 | 1,368.08 | 999.82 |
| Profit After Tax | 615.82 | 341.99 | 520.94 | 1,114.76 | 800.64 |
| Operating Profit After Depreciation | 688.99 | 435.67 | 637.84 | 1,384.10 | 1,070.63 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Fixed Assets | 2,546.71 | 2,398.45 | 1,896.29 | 2,026.67 | 1,823.92 |
| Total Non Current Assets | 3,367.02 | 3,272.81 | 4,261.24 | 4,056.96 | 3,526.30 |
| Total Current Assets | 3,078.56 | 2,910.02 | 2,860.79 | 2,652.02 | 2,462.75 |
| Total Assets | 6,445.58 | 6,182.83 | 7,122.03 | 6,708.98 | 5,989.05 |
| Total Shareholder's Fund | 4,818.20 | 4,370.47 | 5,237.54 | 5,066.97 | 3,219.41 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 803.20 | 723.95 | 552.35 | 1,463.39 | 449.13 |
| Net Cash Used In Investing Activities | -320.61 | -447.60 | -371.97 | -839.74 | -731.22 |
| Net Cash Used In Financing Activities | -437.86 | -261.96 | -217.35 | -597.43 | 154.86 |
Profit and Loss
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Total Revenue | 5,905.38 | 5,152.54 | 5,086.55 | 5,150.79 | 4,267.30 |
| Total Expenses | 5,201.15 | 4,806.61 | 4,428.54 | 3,813.05 | 3,090.51 |
| Profit Before Tax | 704.23 | 345.93 | 658.01 | 1,337.74 | 1,166.79 |
| Profit After Tax | 666.48 | 346.73 | 543.55 | 1,096.54 | 969.40 |
| Operating Profit After Depreciation | 758.70 | 394.93 | 675.03 | 1,350.72 | 1,201.98 |
Balance Sheet
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Fixed Assets | 2,535.66 | 2,377.45 | 1,869.54 | 2,012.07 | 1,268.11 |
| Total Non Current Assets | 3,409.99 | 3,350.20 | 4,329.57 | 4,148.87 | 3,727.40 |
| Total Current Assets | 2,988.55 | 2,780.22 | 2,744.47 | 2,494.60 | 2,151.37 |
| Total Assets | 6,398.54 | 6,130.42 | 7,074.04 | 6,643.47 | 5,878.77 |
| Total Shareholder's Fund | 4,908.91 | 4,414.30 | 5,290.34 | 5,101.81 | 3,346.01 |
Cash Flow
| Particulars (in ₹ Cr.) | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
| Net Cash From Operating Activities | 772.77 | 730.25 | 545.26 | 1,388.48 | 539.75 |
| Net Cash Used In Investing Activities | -329.02 | -460.98 | -368.72 | -836.65 | -821.91 |
| Net Cash Used In Financing Activities | -445.29 | -261.16 | -216.64 | -533.76 | 166.13 |
| Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
|---|---|---|---|---|---|
| Total Revenue | 1,692.74 | 1,647.98 | 1,561.73 | 1,516.98 | 1,630.57 |
| Total Expenses | 1,432.52 | 1,408.71 | 1,324.90 | 1,257.31 | 1,364.25 |
| Profit Before Tax | 177.78 | 180.42 | 157.03 | 182.85 | 184.59 |
| Profit After Tax | 137.70 | 153.14 | 134.54 | 178.21 | 180.45 |
| Operating Profit after Depreciation | 270.08 | 256.87 | 239.25 | 263.27 | 269.21 |
| Particulars (in ₹ Cr.) | 2024-12 | 2024-09 | 2024-06 | 2024-03 | 2023-12 |
|---|---|---|---|---|---|
| Total Revenue | 1,406.09 | 1,580.35 | 1,475.56 | 1,474.55 | 1,588.39 |
| Total Expenses | 1,226.26 | 1,320.86 | 1,184.14 | 1,186.36 | 1,251.25 |
| Profit Before Tax | 103.81 | 200.02 | 213.20 | 216.16 | 256.70 |
| Profit After Tax | 85.81 | 165.78 | 176.19 | 201.87 | 233.24 |
| Operating Profit after Depreciation | 195.29 | 275.55 | 294.57 | 295.41 | 340.44 |
Alembic Pharmaceuticals Ltd Technicals
Support and Resistance
S3
S2
S1
Pivot
R1
R2
R3
S1
839.80
S2
827.65
S3
814.80
Pivot
852.65
R1
864.80
R2
877.65
R3
889.80
Moving Average
20 SMA
878.80
50 SMA
851.32
100 SMA
947.02
200 SMA
1,030.40
Alembic Pharmaceuticals Ltd Corporate Actions
Alembic Pharmaceuticals Ltd
₹11.0/Share
Announcement Date
15 Jul 2024
Record Date
15 Jul 2024
Div Yield
550%
Alembic Pharmaceuticals Ltd Peer Comparison
| Company | Price | Market Cap (in Cr) |
|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹1,751.05 | ₹4,20,135.55 |
| Divis Laboratories Ltd | ₹5,638.35 | ₹1,49,680.48 |
| Cipla Ltd | ₹1,515.45 | ₹1,22,390.34 |
| Torrent Pharmaceuticals Ltd | ₹3,254.85 | ₹1,10,153.97 |
| Mankind Pharma Ltd | ₹2,582.65 | ₹1,06,554.59 |
Alembic Pharmaceuticals Ltd Top Mutal Funds Invested
| Fund Name | AUM |
|---|---|
| Kotak Small Cap Fund | 2.03% |
| DSP Midcap Fund | 1.60% |
| AXIS Small Cap Fund | 0.59% |
| DSP Healthcare Fund | 4.38% |
| DSP ELSS Tax Saver Fund | 0.81% |
Alembic Pharmaceuticals Ltd News
Alembic Pharma receives final approval for Carbamazepine tablets
Alembic Pharmaceuticals announced that it has received final approval from the U.S. Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Carbamazepine Tablets USP, 200 mg.
17 Apr 2025, 12:13 pm
Alembic Pharmaceuticals receives USFDA approval for Carbamazepine Tablets
17 Apr 2025, 12:08 pm
Alembic Pharmaceuticals receives USFDA approval for Pantoprazole sodium for injection
02 Apr 2025, 11:16 am
Alembic Pharma receives USFDA final approval for Pantoprazole Sodium Injection
Alembic Pharmaceuticals (Alembic) announced that it has received final approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Pantoprazole Sodium.
01 Apr 2025, 01:17 pm
Stock Alert: Alembic Pharma, L&T, RIL, M&M, Godrej Properties
24 Mar 2025, 08:37 am
Alembic Pharmaceuticals Ltd Stock Analysis
- Annual revenue for Alembic Pharmaceuticals Ltd increased by 14.61% to ₹5,905.38 crore in FY 2024 from ₹5,152.54 crore in FY 2023.
- Annual Net Profit for Alembic Pharmaceuticals Ltd increased by 92.22% to ₹666.48 crore in FY 2024 from ₹346.73 crore in FY 2023.
- Promoter Shareholding in Alembic Pharmaceuticals Ltd remains unchanged by 0.00% in the most recent quarter, from 69.61% in September 2024 to 69.61% in December 2024.
- Alembic Pharmaceuticals Ltd delivered a 1-year return of -11.77% compared to the Nifty 50, which provided a return of 5.82% as of the last trading session.
- Alembic Pharmaceuticals Ltd share price moved down by 0.24% from its previous close of INR ₹851.95. The latest Alembic Pharmaceuticals Ltd share price is INR ₹849.90.
- Alembic Pharmaceuticals Ltd share price today has been at a low of 842.75 and a high of 860.95. Over the past 52 weeks, the Alembic Pharmaceuticals Ltd share price has seen a low of 725.20 and a high of 1,303.90.
About Alembic Pharmaceuticals Ltd
Alembic Pharmaceuticals Ltd stands as a prominent figure in the pharmaceutical industry. It boasts a rich history dating back to its founding in 1907. With over a century of experience, this Gujarat-based company has established itself as a key player in the healthcare sector. It specializes in the manufacture and marketing of branded and generic drugs, as well as active pharmaceutical ingredients (APIs).
Headquartered in Vadodara, Alembic Pharmaceuticals is under the stewardship of the Amin family. Chirayu Amin serves as the Chairman, while Pranav Amin and Shaunak Amin hold positions as Managing Directors. Alembic’s main promoter is Nirayu Limited, which owns a 35.63% stake in the company.
Alembic’s product portfolio is diverse. The company’s products includes antibiotics, anti-infectives, analgesics, and anti-inflammatory drugs, showcasing its expertise in this area. It is not the largest in terms of market share or capitalization. However, Alembic has cultivated a strong reputation in domestic and international markets. This global reach positions them as an influential entity in the pharmaceutical landscape.
The company’s success is driven by a team of managerial promoters who manage operations from the registered office in Vadodara, Gujarat. Their commitment to innovation and quality has allowed Alembic to maintain an edge in its industry. The company’s registrars are also located in Vadodara.
In essence, Alembic Pharmaceuticals Ltd. represents a blend of historical legacy and modern pharmaceutical prowess. Its century-long journey and global presence collectively paint the picture of a company that continues to play a major role in shaping the pharmaceutical sector.
In its early years, Alembic was a pioneer in the Indian pharmaceutical industry. In the 1940s, the company had expanded its product range to include cough syrups and sulfur drugs. This marked the beginning of Alembic’s journey towards becoming a household name in India. The company continued to innovate. In 1961, it inaugurated a dedicated penicillin plant, which was a significant milestone.
The 1970s were a transformative decade for Alembic. In 1971, the company began manufacturing erythromycin, an antibiotic, for the first time in India. This led to the launch of Althrocin, a brand of erythromycin, which became one of the top-selling antibiotics in the country by 1997. Alembic’s commitment to innovation was further demonstrated in the 1990s. This is when it started producing synthetic, organic active pharmaceutical ingredients (APIs).
In the 2000s, Alembic continued to grow and diversify. The company received ISO 14000 certification for its facilities in Vadodara, highlighting its commitment to environmental standards. In 2007, Alembic acquired the non-oncology business of Dabur Pharma Ltd., further expanding its product portfolio. The company also ventured into the production of cephalosporin C, a key antibiotic.
A significant development in Alembic’s history was its demerger from Alembic Ltd. in 2010, leading to the formation of Alembic Pharmaceuticals Ltd. as a separate entity. This move allowed the company to focus more on its core pharmaceutical business. In 2011, Alembic Pharmaceuticals was listed on the BSE and the NSE.
In recent years, Alembic has made significant strides in the global market. The company established a strong presence in the United States, achieving sales milestones. It even received the FDA approvals for its manufacturing facilities. Alembic also created strategic partnerships and joint ventures to enhance its capabilities and market reach. For instance, in 2016, it formed a joint venture with Orbicular to develop dermatology products for the international market.
Alembic’s success can be attributed to its unwavering commitment to quality and sustainability. The company invests heavily in research and development. This is to stay ahead of industry trends and meet the evolving needs of its customers. Alembic’s manufacturing facilities are equipped with the latest technology. They also adhere to stringent quality standards. The company’s focus on sustainability is evident in its efforts to reduce its environmental footprint through various initiatives.
Looking ahead, Alembic aims to continue its growth trajectory by expanding its market share and revenue. The company plans to explore new markets and enhance its product offerings. With its rich legacy and commitment to innovation, Alembic is well-positioned to meet the changing needs of the pharmaceutical industry. It is also ready to contribute to the development of safe and effective medications for patients worldwide.
Overall, Alembic Pharmaceuticals Ltd. has come a long way since its inception in 1907. From its early days of manufacturing tinctures and alcohol to becoming a global player in the pharmaceutical industry, Alembic’s journey is a testament to its resilience and commitment to quality.
Headquartered in Vadodara, Alembic Pharmaceuticals is under the stewardship of the Amin family. Chirayu Amin serves as the Chairman, while Pranav Amin and Shaunak Amin hold positions as Managing Directors. Alembic’s main promoter is Nirayu Limited, which owns a 35.63% stake in the company.
Alembic’s product portfolio is diverse. The company’s products includes antibiotics, anti-infectives, analgesics, and anti-inflammatory drugs, showcasing its expertise in this area. It is not the largest in terms of market share or capitalization. However, Alembic has cultivated a strong reputation in domestic and international markets. This global reach positions them as an influential entity in the pharmaceutical landscape.
The company’s success is driven by a team of managerial promoters who manage operations from the registered office in Vadodara, Gujarat. Their commitment to innovation and quality has allowed Alembic to maintain an edge in its industry. The company’s registrars are also located in Vadodara.
In essence, Alembic Pharmaceuticals Ltd. represents a blend of historical legacy and modern pharmaceutical prowess. Its century-long journey and global presence collectively paint the picture of a company that continues to play a major role in shaping the pharmaceutical sector.
Alembic Pharmaceuticals’ Journey Since 1907
Alembic Pharmaceuticals Ltd. has a rich history that dates back to 1907. Founded in Vadodara, Gujarat, the company began as Alembic Chemical Works Company Limited. Initially, it focused on manufacturing tinctures and alcohol. Over the years, Alembic has evolved into a major player in the pharmaceutical industry. The company is mainly known for its innovation and commitment to quality.In its early years, Alembic was a pioneer in the Indian pharmaceutical industry. In the 1940s, the company had expanded its product range to include cough syrups and sulfur drugs. This marked the beginning of Alembic’s journey towards becoming a household name in India. The company continued to innovate. In 1961, it inaugurated a dedicated penicillin plant, which was a significant milestone.
The 1970s were a transformative decade for Alembic. In 1971, the company began manufacturing erythromycin, an antibiotic, for the first time in India. This led to the launch of Althrocin, a brand of erythromycin, which became one of the top-selling antibiotics in the country by 1997. Alembic’s commitment to innovation was further demonstrated in the 1990s. This is when it started producing synthetic, organic active pharmaceutical ingredients (APIs).
In the 2000s, Alembic continued to grow and diversify. The company received ISO 14000 certification for its facilities in Vadodara, highlighting its commitment to environmental standards. In 2007, Alembic acquired the non-oncology business of Dabur Pharma Ltd., further expanding its product portfolio. The company also ventured into the production of cephalosporin C, a key antibiotic.
A significant development in Alembic’s history was its demerger from Alembic Ltd. in 2010, leading to the formation of Alembic Pharmaceuticals Ltd. as a separate entity. This move allowed the company to focus more on its core pharmaceutical business. In 2011, Alembic Pharmaceuticals was listed on the BSE and the NSE.
In recent years, Alembic has made significant strides in the global market. The company established a strong presence in the United States, achieving sales milestones. It even received the FDA approvals for its manufacturing facilities. Alembic also created strategic partnerships and joint ventures to enhance its capabilities and market reach. For instance, in 2016, it formed a joint venture with Orbicular to develop dermatology products for the international market.
Alembic’s success can be attributed to its unwavering commitment to quality and sustainability. The company invests heavily in research and development. This is to stay ahead of industry trends and meet the evolving needs of its customers. Alembic’s manufacturing facilities are equipped with the latest technology. They also adhere to stringent quality standards. The company’s focus on sustainability is evident in its efforts to reduce its environmental footprint through various initiatives.
Looking ahead, Alembic aims to continue its growth trajectory by expanding its market share and revenue. The company plans to explore new markets and enhance its product offerings. With its rich legacy and commitment to innovation, Alembic is well-positioned to meet the changing needs of the pharmaceutical industry. It is also ready to contribute to the development of safe and effective medications for patients worldwide.
Overall, Alembic Pharmaceuticals Ltd. has come a long way since its inception in 1907. From its early days of manufacturing tinctures and alcohol to becoming a global player in the pharmaceutical industry, Alembic’s journey is a testament to its resilience and commitment to quality.
FAQ’s
What is the share price of Alembic Pharmaceuticals Ltd today?
Alembic Pharmaceuticals Ltd share price as on 17 Apr 2025 is ₹
849.9
What is the Market Cap of Alembic Pharmaceuticals Ltd?
The market cap of Alembic Pharmaceuticals Ltd stock is ₹16,705.90 Cr.
What is the PE Ratio of Alembic Pharmaceuticals Ltd?
The Price to Earnings (P/E) Ratio of Alembic Pharmaceuticals Ltd is 28.97
What is the PB Ratio of Alembic Pharmaceuticals Ltd?
The Price to Book (P/B) Ratio of Alembic Pharmaceuticals Ltd is 3.93
What is the 52 week high of Alembic Pharmaceuticals Ltd Share Price?
The 52 week high of Alembic Pharmaceuticals Ltd share price stands at ₹1,303.90
What is the 52 week low of Alembic Pharmaceuticals Ltd Share Price?
The 52 week low of Alembic Pharmaceuticals Ltd share price stands at ₹725.20
How can I buy shares of Alembic Pharmaceuticals Ltd?
Simply open a demat account with Torus Digital and place an order to buy shares of Alembic Pharmaceuticals Ltd.
Open FREE
3-in-1 Account
for all your banking, trading and demat needs
Trade in stocks,
derivatives and F&O
